reports
- Ahmed Ben Salem
- Ahmed Ben Salem
- Oliver Metzger
- Stephan Wulf
Dermapharm Holding SE : Smooth integration of Arkopharma and declining...
>2023 net earnings also burdened by accounting-related charges - While the final sales and EBITDA figures confirmed the preliminary results released on 14 March, the net result for 2023 published for the first time obviously led to disappointment in the market. The significant increase in financial expenses (c +400% to € 73m), together with the lower operating result (-25%) due to the absence of the vaccine business, led to a significantly lower net result of € 60.5m ...
Dermapharm Holding SE: 1 director
A director at Dermapharm Holding SE bought 60,000 shares at 33.000EUR and the significance rating of the trade was 67/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years...
EQS-News: Dermapharm Holding SE erfüllt alle Erwartungen trotz multipl...
EQS-News: Dermapharm Holding SE / Schlagwort(e): Jahresergebnis/Jahresbericht Dermapharm Holding SE erfüllt alle Erwartungen trotz multipler gesamtwirtschaftlicher Herausforderungen 28.03.2024 / 07:30 CET/CEST Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich. Dermapharm Holding SE erfüllt alle Erwartungen trotz multipler gesamtwirtschaftlicher Herausforderungen » Konzernumsatz um 10,8 % gegenüber Vorjahr auf 1.135,4 Mio. € gestiegen » Bereinigtes Konzern-EBITDA um 13,8 % auf 310,2 Mio. € gesunken » Bereinigte Konzern-EBITDA-Marge liegt be...
EQS-News: Dermapharm Holding SE fulfils all expectations despite multi...
EQS-News: Dermapharm Holding SE / Key word(s): Annual Results/Annual Report Dermapharm Holding SE fulfils all expectations despite multiple macroeconomic challenges 28.03.2024 / 07:30 CET/CEST The issuer is solely responsible for the content of this announcement. Dermapharm Holding SE fulfils all expectations despite multiple macroeconomic challenges » Consolidated revenue up year on year by 10.8% to EUR 1,135.4 million » Adjusted consolidated EBITDA declines 13.8% to EUR 310.2 million » Adjusted consolidated EBITDA margin at 27.3% » Earnings decline as boom from ...
- Benoit Valleaux
- Steven Gould
- Thomas Zlowodzki
ODDO BHF Small & MIDCAP MORNING NEWS - 03/14/2024
Banks tick all the boxes in the market’s current configuration: search for discounted sectors, cyclical momentum, sectors driven by long-term interest rates that remain high and shareholder returns through very high dividend yields. Technical analysis reveals a strong conviction since early March, and this should continue. We prefer banks in southern Europe, where the macro outlook is brighter. Alongside CaixaBank, which we are maintaining in our list of European Large Cap stocks, we ...
CSGN CREDIT SUISSE GROUP AG
UBSN UBS GROUP AG
BNP BNP PARIBAS SA CLASS A
DBK DEUTSCHE BANK AG
CBK COMMERZBANK AG
BFIT BASIC-FIT NV
PBB DEUTSCHE PFANDBRIEFBANK AG
IDL ID LOGISTICS GROUP
INF INFOTEL SA
GLE SOCIETE GENERALE S.A. CLASS A
KBC KBC GROUP N.V.
LXS LANXESS AG
ASY ASSYSTEM SA
KCO KLOECKNER & CO SE
JCQ JACQUET METALS SA
CDA COMPAGNIE DES ALPES SA
ISP INTESA SANPAOLO S.P.A.
BCP BANCO COMERCIAL PORTUGUES S.A.
SHA SCHAEFFLER AG
IDIP INSTITUT DE DEVELOPPEMENT INDUSTRIEL SCA
ERG ERG S.P.A.
BKT BANKINTER SA
VLK VAN LANSCHOT KEMPEN NV CERT. OF SHS
UCG UNICREDIT S.P.A.
CABK CAIXABANK SA
INGA ING GROEP NV
SAN BANCO SANTANDER S.A.
UNI UNICAJA BANCO S.A.
BBVA BANCO BILBAO VIZCAYA ARGENTARIA S.A.
DMP DERMAPHARM HOLDING SE
MOR MORPHOSYS AG
SAB BANCO DE SABADELL SA
2CRSI 2CRSI SA
TITC TITAN CEMENT INTERNATIONAL N.V.
SRAIL STADLER RAIL AG
SFQ SAF-HOLLAND SE
BLV BELIEVE SA
BAI BENEVOLENTAI
- Jerôme Bodin
- Thomas Zlowodzki
ODDO BHF Small & MIDCAP MORNING NEWS - 14/03/2024
Les banques cochent toutes les cases de la configuration de marché actuelle : recherche de secteurs décotés, momentum cyclique, secteurs portés par des taux longs qui restent hauts, retour à l’actionnaire via un très haut dividend yield. L’analyse technique montre une forte conviction depuis début mars, qui devrait se poursuivre. Nous favorisons les banques du sud de l’Europe, à la macro plus avenante. Aux côtés de CaixaBank, que nous conservons dans notre liste de valeurs Large Caps ...
IDL ID LOGISTICS GROUP
INF INFOTEL SA
LXS LANXESS AG
ASY ASSYSTEM SA
KCO KLOECKNER & CO SE
JCQ JACQUET METALS SA
CDA COMPAGNIE DES ALPES SA
SHA SCHAEFFLER AG
IDIP INSTITUT DE DEVELOPPEMENT INDUSTRIEL SCA
ERG ERG S.P.A.
DMP DERMAPHARM HOLDING SE
MOR MORPHOSYS AG
2CRSI 2CRSI SA
TITC TITAN CEMENT INTERNATIONAL N.V.
SRAIL STADLER RAIL AG
SFQ SAF-HOLLAND SE
BLV BELIEVE SA
BAI BENEVOLENTAI
- Oliver Metzger
- Stephan Wulf
Dermapharm Holding SE : Preliminary 2023 results broadly in line with ...
>2023 EBITDA at the upper end of the guidance – slightly below our estimates - Dermapharm released preliminary revenue for 2023 of € 1.135m (+11%), 2% above our and the consensus’ estimates. Adj. EBITDA came in at € 310.2m (-14%) slightly below our estimates (€ 314m) but above the cons. (€ 308m). The 2023 guidance was € 300-310m. The EBITDA decline of 14% reflects the end of the BioNTech collaboration for the production of the Covid vaccine, which stopped at the end o...
EQS-News: Dermapharm Holding SE hits upper end of guidance range for a...
EQS-News: Dermapharm Holding SE / Key word(s): Annual Results/Preliminary Results Dermapharm Holding SE hits upper end of guidance range for adjusted EBITDA, primarily due to steadily growing international presence in branded business 14.03.2024 / 07:30 CET/CEST The issuer is solely responsible for the content of this announcement. Dermapharm Holding SE hits upper end of guidance range for adjusted EBITDA, primarily due to steadily growing international presence in branded business » Consolidated revenue up 10.8% year on year to EUR 1,135.4 million » Adjusted cons...
EQS-News: Dermapharm Holding SE erreicht das obere Ende der Prognose d...
EQS-News: Dermapharm Holding SE / Schlagwort(e): Jahresergebnis/Vorläufiges Ergebnis Dermapharm Holding SE erreicht das obere Ende der Prognose des bereinigten Konzern-EBITDAs vor allem wegen stetig wachsender internationaler Präsenz im Markengeschäft 14.03.2024 / 07:30 CET/CEST Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich. Dermapharm Holding SE erreicht das obere Ende der Prognose des bereinigten Konzern-EBITDAs vor allem wegen stetig wachsender internationaler Präsenz im Markengeschäft » Konzernumsatz wächst um 10,8 % gegenüber Vo...
EQS-News: Dermapharm Holding SE builds on success in Q3 2023
EQS-News: Dermapharm Holding SE / Key word(s): 9 Month figures/Quarterly / Interim Statement Dermapharm Holding SE builds on success in Q3 2023 15.11.2023 / 07:30 CET/CEST The issuer is solely responsible for the content of this announcement. Dermapharm Holding SE builds on success in Q3 2023 Consolidated revenue and EBITDA (adjusted) stay on course, climbing to EUR 866.6 million and EUR 243.8 million, respectively Expansion driven by strong organic growth in the diversified product portfolio and the acquisition of the Arkopharma Group Adjusted consolidated EBITDA...
EQS-News: Dermapharm Holding SE setzt im dritten Quartal 2023 ihren E...
EQS-News: Dermapharm Holding SE / Schlagwort(e): 9-Monatszahlen/Quartals-/Zwischenmitteilung Dermapharm Holding SE setzt im dritten Quartal 2023 ihren Erfolgskurs fort 15.11.2023 / 07:30 CET/CEST Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich. Dermapharm Holding SE setzt im dritten Quartal 2023 ihren Erfolgskurs fort Konzernumsatz und -EBITDA (bereinigt) wachsen weiter planmäßig auf 866,6 Mio. € bzw. 243,8 Mio. € Wachstumstreiber sind ein starkes organisches Wachstum des diversifizierten Produktportfolios und die akquirierte Arkopharma...
- Ahmed Ben Salem
ODDO BHF Small & MIDCAP MORNING NEWS - 10/13/2023
In an increasingly challenging macroeconomic environment, X-Fab can draw on a number of strengths to stand out, including 1/ the rollout of so-called take-or-pay agreements, 2/ exposure to buoyant markets and 3/ the repositioning of its fab in France. Management will also have to push ahead with its vast investment plan to meet customers' long-term needs and deliver on its roadmap (2022-26 adjusted EBITDA CAGR = +30%). In this report, we will look at this new profile, which is less cy...
FP TOTAL SE
EQNR EQUINOR ASA
GALP GALP ENERGIA SGPS SA CLASS B
ALLIX WALLIX GROUP SA
SLB.N SCHLUMBERGER NV
GTT GAZTRANSPORT & TECHNIGAZ SA
SBMO SBM OFFSHORE NV
EURN EURONAV NV
GBT GUERBET SA
PGS PGS ASA
ENI ENI S.P.A.
TW11 TENARIS S.A.
P2F PETROFAC LIMITED
REP REPSOL SA
SOC SUBSEA 7 S.A.
BKT BANKINTER SA
SBO SCHOELLER-BLECKMANN OILFIELD EQUIPMENT AG
CABK CAIXABANK SA
SAN BANCO SANTANDER S.A.
TRE TECNICAS REUNIDAS SA
DR0 DEUTSCHE ROHSTOFF AG
TEC TECHNIPFMC PLC
UNI UNICAJA BANCO S.A.
BP. BP P.L.C.
CGG CGG
BBVA BANCO BILBAO VIZCAYA ARGENTARIA S.A.
DMP DERMAPHARM HOLDING SE
ENOG ENERGEAN PLC
SAB BANCO DE SABADELL SA
NSI NSI N.V.
THEP THERMADOR HOLDING SA
TOM2 TOMTOM NV
VK VALLOUREC SA
TE TECHNIP ENERGIES NV
FUR FUGRO NV
EBUS EBUSCO HLDG NV
SHEL SHELL PLC
SPM SAIPEM S.P.A.
STM STABILUS SE
- Ahmed Ben Salem
ODDO BHF Small & MIDCAP MORNING NEWS - 13/10/2023
Face à un environnement économique de plus en plus challenging, X-Fab peut compter sur plusieurs atouts pour se distinguer comme 1/ la mise en œuvre de contrats "take or pay", 2/ l’exposition à des débouchés porteurs et 3/ le repositionnement de son usine en France. Les dirigeants doivent également exécuter un vaste plan d'investissements pour répondre aux besoins à long terme des clients et délivrer leur feuille de route (TMVA EBITDA ajusté 2022-2026 = +30%). Nous revenons dans cette...
FP TOTAL SE
EQNR EQUINOR ASA
GALP GALP ENERGIA SGPS SA CLASS B
ALLIX WALLIX GROUP SA
SLB.N SCHLUMBERGER NV
GTT GAZTRANSPORT & TECHNIGAZ SA
SBMO SBM OFFSHORE NV
EURN EURONAV NV
GBT GUERBET SA
PGS PGS ASA
ENI ENI S.P.A.
TW11 TENARIS S.A.
P2F PETROFAC LIMITED
REP REPSOL SA
SOC SUBSEA 7 S.A.
BKT BANKINTER SA
SBO SCHOELLER-BLECKMANN OILFIELD EQUIPMENT AG
CABK CAIXABANK SA
SAN BANCO SANTANDER S.A.
TRE TECNICAS REUNIDAS SA
DR0 DEUTSCHE ROHSTOFF AG
TEC TECHNIPFMC PLC
UNI UNICAJA BANCO S.A.
BP. BP P.L.C.
CGG CGG
BBVA BANCO BILBAO VIZCAYA ARGENTARIA S.A.
DMP DERMAPHARM HOLDING SE
ENOG ENERGEAN PLC
SAB BANCO DE SABADELL SA
NSI NSI N.V.
THEP THERMADOR HOLDING SA
TOM2 TOMTOM NV
VK VALLOUREC SA
TE TECHNIP ENERGIES NV
FUR FUGRO NV
EBUS EBUSCO HLDG NV
SHEL SHELL PLC
SPM SAIPEM S.P.A.
STM STABILUS SE
- Oliver Metzger
- Stephan Wulf
Dermapharm Holding SE : Positive impression from CMD – organic growth ...
>Higher expectations for organic revenue and EBITDA growth - At Dermapharm's CMD in Nice, the focus was on information about Arkopharma, which has been consolidated since January 2023. The company provided a deep insight into the structure and finances of the new subsidiary as well as the expected and already achieved synergies with Dermapharm's core business. The company also provided insight into the group's current operating performance and provided key financial m...
EQS-News: Dermapharm Holding SE veröffentlicht Halbjahresfinanzbericht...
EQS-News: Dermapharm Holding SE / Schlagwort(e): Halbjahresergebnis/Halbjahresbericht Dermapharm Holding SE veröffentlicht Halbjahresfinanzbericht 2023 und bestätigt Prognose für das Gesamtjahr 2023 29.08.2023 / 07:30 CET/CEST Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich. Dermapharm Holding SE veröffentlicht Halbjahresfinanzbericht 2023 und bestätigt Prognose für das Gesamtjahr 2023 Konzernumsatz und -EBITDA (bereinigt) wachsen weiter planmäßig auf 582,1 Mio. € bzw. 168,0 Mio. € gegenüber der entsprechenden Vorjahresperiode Wachstum...
EQS-News: Dermapharm Holding SE publishes H1 2023 financial report, ...
EQS-News: Dermapharm Holding SE / Key word(s): Half Year Results/Half Year Report Dermapharm Holding SE publishes H1 2023 financial report, confirms outlook for 2023 overall 29.08.2023 / 07:30 CET/CEST The issuer is solely responsible for the content of this announcement. Dermapharm Holding SE publishes H1 2023 financial report, confirms outlook for 2023 overall Consolidated revenue and EBITDA (adjusted) stay on course, climbing year on year to EUR 582.1 million and EUR 168.0 million, respectively Expansion driven by Arkopharma Group and strong organic growth in...
- Thijs Berkelder
- Oliver Metzger
- Stephan Wulf
Dermapharm Holding SE : Guidance confirmed at upper end of range – in ...
>H1 revenues in line, adj. EBITDA above estimates - Dermapharm released prel. H1 2023 revenue and adj. EBITDA figures. Group’s revenues came in at € 582m (+23%) in line with ODDO BHF (€582,1m) and consensus (€580.3m), adj. EBITDA was at €168m (+13%) better than we (€ 163m) and consensus (€ 162.8m) expected. Looking at Q2 results, revenues of €263m were c. 10% above previous year’s level, while H1 2023’s adj. EBITDA of € 62.2m came some 15% below Q2 2022. This decrease...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.